Hematologic Oncology

JAK plays an important role in the formation and development of blood cells, and defects in the gene have been identified in myeloproliferative neoplasms.

Dr. Eric Larsen, from the Maine Children's Cancer Program, Discusses Outcomes for AYA Patients With Acute Lymphoblastic Leukemia

Dr. Mathias Rummel, from University Hospital Giessen in Germany, on Bendamustine Plus Rituximab in Indolent and Mantle Cell Lymphomas

Bendamustine should become the preferred chemotherapy standard of care in initial combination regimens for indolent lymphomas and mantle cell lymphoma.

Adolescent and young adult patients between the ages of 16 and 30 had poorer outcomes when given the same treatment regimen as younger acute lymphoblastic leukemia patients.

Dr. Andre Goy, from John Theurer Cancer Center, Highlights Research From the 2012 ASCO Meeting.

To learn more about how photopheresis can help patients fight the symptoms of CTCL, OncologyLive spoke with Dennis Parenti, MD, vice president of Clinical Affairs for Therakos.

At this year's annual NCCN conference, the organization presented updates in 13 areas, including specific disease states and general screening methods.

The demonstrated impact of imatinib mesylate on outcomes for patients with CML shifted the oncology paradigm to an intensive search for relevant molecular target.

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

Dr. Stephen Ansell, from the Mayo Clinic, on Treating Patients With Waldenström Macroglobulinemia

Discussion with Andrew D. Zelenetz, MD, PhD, on a number of new therapies and interesting challenges regarding the treatment of patients with both Hodgkin and non- Hodgkin lymphoma.

Dr. Harry Erba, from University of Michigan Health System, Discusses Molecular Monitoring for CML

Michael Eckenfels, RN, OCN, from MD Anderson Cancer Center, on Changes to the Bortezomib Delivery Route.

William G. Wierda, MD, PhD, discussed the management of chronic lymphocytic leukemia at the 16th Annual International Congress on Hematologic Malignancies.

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, Discusses Treatment Options for DLBCL

Results of recent trials investigating novel therapies for chronic lymphocytic leukemia were discussed at the 16th Annual International Congress on Hematologic Malignancies.

The prognosis for a significant fraction of DLBCL patients that relapse while receiving the current standard treatment of R-CHOP-21 remains poor.

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

Dr. Kieron Dunleavy, from the National Cancer Institute, Discusses Treatment Options for Primary Mediastinal B Cell Lymphoma

There are many ideas that if followed will not just help you to "do your time" during fellowship, but contribute to the internal medicine residency program.

There is no such thing as a typical day. Our days are punctuated by the unexpected and our field is so diverse that we often change what we do over the course of our careers. Time alters us and our field.

Elotuzumab demonstrated notable response rates as combination therapy in a phase II study of patients with relapsed or refractory multiple myeloma.

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, on Targeted Therapies for Diffuse Large B-cell Lymphoma

Dr. Harry Erba, from the University of Michigan Health System, Discusses the Frontline Treatment of CML